Germ-zapping robot maker gets new digs as business grows
FacebookTwitterEmail
Lead Mechanical Engineer Deepak Jayaraj, left, and Xenex CEO Morris Miller, right,pose with one of the company s product, LightStrike Germ-Zapping Robots, at their new offices north of the San Antonio International Airport, Tuesday, Jan. 19, 2021. The company has sold the robots, that use UV rays to kill germs, to the San Antonio Spurs, hospitals throughout the country and the Texas State Capitol.Jerry Lara / Staff photographer
San Antonio’s disinfecting robot manufacturer, Xenex, kicked off 2021 by expanding both its facilities and its business.
With sales soaring 600 percent in 2020, due largely to the COVID-19 pandemic, the privately held firm outgrew its old space. But it found a new home in a business park two miles away, near Wurzbach Parkway and San Antonio International Airport.
New Standard for Borderline Resectable Pancreatic Cancer medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
This article is a collaboration between MedPage Today and:
Neoadjuvant chemoradiation failed to improve survival in borderline-resectable pancreatic cancer as compared with chemotherapy alone, a randomized trial showed.
Patients randomized to chemotherapy alone had an 18-month OS rate of 66.4% versus 47.3% for the group that received chemoradiation (CRT). A futility analysis showed that adding stereotactic body radiation therapy (SBRT) was unlikely to improve overall survival (OS). Preoperative modified FOLFIRINOX was associated with favorable overall survival relative to historical data in patients with borderline-resectable pancreatic ductal adenocarcinoma, Matthew H.G. Katz, MD, of the University of Texas MD Anderson Cancer Center in Houston, said during the Gastrointestinal Cancers Symposium virtual meeting. We cannot conclude efficacy for modified FOLFIRINOX plus radiation, as statistical requirements were not met.
In an effort to address a major challenge when analyzing large single-cell RNA-sequencing datasets, researchers from the University of Texas MD Anderson Cancer
2021 Research Grant Recipients Announced by the VHL Alliance
Global Research Program Supports Curing Cancer through VHL
News provided by
Share this article
Share this article
BOSTON, Jan. 19, 2021 /PRNewswire/ The VHL Alliance (VHLA) today announced the 2021 recipients of the VHLA Competitive Research Grant Program. This year, three grantees were chosen. Scientists are increasingly aware that curing von Hippel-Lindau disease, a genetic form of cancer – is a key step to curing cancer, leading to a significant increase in the quality of research grant applicants in the program year after year.
Over 20 top VHLA researchers from across the US, Canada, and Europe were involved in reviewing and selecting those projects which have the greatest potential to make advances toward Curing Cancer through VHL. For the second year in a row, responding to the increase in quality applications, the VHLA Board of Directors voted to expand the annual budget for research.